









Markets
/
Stocks
/
nasdaq-trib
/

Trinity Biotech PLC

TRIB

0.585USD

-0.016-2.73%

Market hours （ET）Quotes delayed by 15 min

4.85MMarket Cap

LossP/E TTM



Trinity Biotech PLC

0.585

-0.016-2.73%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Trinity Biotech PLC

Currency: USD Updated: 2026-03-27

Key Insights

Trinity Biotech PLC's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 152 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Trinity Biotech PLC's Score

Industry at a Glance

Industry Ranking

152 / 208

Overall Ranking

440 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Trinity Biotech PLC Highlights

StrengthsRisks

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Growing

The company is in a growing phase, with the latest annual income totaling USD 61.55M.

Overvalued

The company’s latest PE is -0.12, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 2.85M shares, increasing 11.27% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 20.26K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 8.62.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Trinity Biotech PLC is 6.48, ranking 146 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 15.15M, representing a year-over-year increase of 3.24%, while its net profit experienced a year-over-year increase of 29.19%.

Score

Industry at a Glance

Previous score

6.14

Change

0.34



Financials

3.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.19

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.67

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Trinity Biotech PLC's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Trinity Biotech PLC is 6.90, ranking 138 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.12, which is -13.42% below the recent high of -0.10 and -360.60% above the recent low of -0.54.

Score

Industry at a Glance

Previous score

6.90

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 152/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for Trinity Biotech PLC. The Healthcare Equipment & Supplies industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Trinity Biotech PLC is 4.90, ranking 186 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.76 and the support level at 0.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.98

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.018

Sell

RSI(14)

37.569

Neutral

STOCH(KDJ)(9,3,3)

6.817

Oversold

ATR(14)

0.072

Low Volatility

CCI(14)

-87.399

Neutral

Williams %R

95.456

Oversold

TRIX(12,20)

-0.698

Sell

StochRSI(14)

11.273

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.606

Sell

MA10

0.657

Sell

MA20

0.682

Sell

MA50

0.743

Sell

MA100

0.829

Sell

MA200

0.911

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Trinity Biotech PLC is 5.00, ranking 114 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 61.97%, representing a quarter-over-quarter increase of 380.25%. The largest institutional shareholder is James Simons, holding a total of 20.26K shares, representing 0.11% of shares outstanding, with 73.68% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

MiCo IVD Holdings, LLC

2.24M

+400.00%

Hunter Associates Investment Management LLC

487.11K

+456.18%

Williams & Novak Wealth Management, LLC

12.00K

+172.73%

Two Sigma Investments, LP

36.23K

+1101.76%

Moss Adams Wealth Advisors LLC

25.67K

+400.02%

Inspirion Wealth Advisors, LLC

10.00K

+400.00%

Cambridge Investment Research Advisors, Inc.

22.28K

+400.00%

Raymond James & Associates, Inc.

20.32K

+300.77%

Renaissance Technologies LLC

Star Investors

171.36K

+1404.10%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Trinity Biotech PLC is 1.41, ranking 190 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.74. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.